Open-label, Multicenter, Phase 1/2 Study of Mogamulizumab in Combination With Nivolumab in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 02 Feb 2017
At a glance
- Drugs Mogamulizumab (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Kyowa Hakko Kirin
- 20 Jan 2017 Planned number of patients changed from 187 to 188.
- 20 Jan 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Mar 2018.
- 09 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.